301 related articles for article (PubMed ID: 15358169)
1. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
[TBL] [Abstract][Full Text] [Related]
2. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
Gils A; Knockaert I; Declerck PJ
Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
[TBL] [Abstract][Full Text] [Related]
3. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
4. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
5. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
Gils A; Declerck PJ
J Biol Chem; 1997 May; 272(19):12662-6. PubMed ID: 9139722
[TBL] [Abstract][Full Text] [Related]
6. 19F NMR studies of plasminogen activator inhibitor-1.
Abbott GL; Blouse GE; Perron MJ; Shore JD; Luck LA; Szabo AG
Biochemistry; 2004 Feb; 43(6):1507-19. PubMed ID: 14769027
[TBL] [Abstract][Full Text] [Related]
7. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
9. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
J Pharm Belg; 2000; 55(2):57-8. PubMed ID: 10842928
[TBL] [Abstract][Full Text] [Related]
10. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
Kvassman JO; Verhamme I; Shore JD
Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
[TBL] [Abstract][Full Text] [Related]
12. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.
Aertgeerts K; De Ranter CJ; Booth NA; Declerck PJ
J Struct Biol; 1997 Apr; 118(3):236-42. PubMed ID: 9169233
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
[TBL] [Abstract][Full Text] [Related]
14. Structural determinants in the stability of the serpin/proteinase complex.
De Taeye B; Verbeke K; Compernolle G; Biesemans W; Gils A; Declerck PJ
Biochem Biophys Res Commun; 2003 Aug; 307(3):529-34. PubMed ID: 12893254
[TBL] [Abstract][Full Text] [Related]
15. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
[TBL] [Abstract][Full Text] [Related]
16. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
Gils A; Lu J; Aertgeerts K; Knockaert I; Declerck PJ
FEBS Lett; 1997 Sep; 415(2):192-5. PubMed ID: 9350994
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.
Rezaie AR
Biochemistry; 1998 Sep; 37(38):13138-42. PubMed ID: 9748320
[TBL] [Abstract][Full Text] [Related]
18. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
19. High quality structure of cleaved PAI-1-stab.
Dewilde M; Strelkov SV; Rabijns A; Declerck PJ
J Struct Biol; 2009 Feb; 165(2):126-32. PubMed ID: 19059484
[TBL] [Abstract][Full Text] [Related]
20. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
Vleugels N; Leys J; Knockaert I; Declerck PJ
Thromb Haemost; 2000 Nov; 84(5):871-5. PubMed ID: 11127870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
